OS Therapies (OSTX) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OS Therapies (OSTX) has outperformed Spero Therapeutics (SPRO) over the past year, losing 53.0% versus a loss of 67.9%. Spero Therapeutics is the larger company by market cap ($43.2 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | SPRO |
|---|---|---|
| Share price | $0.803 | $0.742 |
| Market cap | $42.00M | $43.23M |
| 1-day change | -2.12% | -10.20% |
| YTD return | -42.64% | -68.15% |
| 1-year return | -53.04% | -67.88% |
| 5-year return | — | -95.09% |
| Forward P/E | 2.29 | — |
| EPS (TTM) | $-1.08 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | $-28.75M | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $2.25 | $3.08 |
| 52-week low | $0.58 | $0.73 |
| Distance from 52-week high | -64.31% | -75.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +958.53% | +573.85% |
| Average volume | 722.66K | 530.46K |
| Shares outstanding | 52.30M | 58.26M |
| Employees | 4 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed SPRO by 14.8 percentage points over the past year.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
OSTX vs SPRO FAQ
Which is bigger, OS Therapies or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $42.00M for OS Therapies (OSTX).
Which stock has performed better over the past year, OSTX or SPRO?
OSTX returned -53.04% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.